Cargando…
Dynamic causal modelling of immune heterogeneity
An interesting inference drawn by some COVID-19 epidemiological models is that there exists a proportion of the population who are not susceptible to infection—even at the start of the current pandemic. This paper introduces a model of the immune response to a virus. This is based upon the same sort...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8167139/ https://www.ncbi.nlm.nih.gov/pubmed/34059775 http://dx.doi.org/10.1038/s41598-021-91011-x |
_version_ | 1783701631433441280 |
---|---|
author | Parr, Thomas Bhat, Anjali Zeidman, Peter Goel, Aimee Billig, Alexander J. Moran, Rosalyn Friston, Karl J. |
author_facet | Parr, Thomas Bhat, Anjali Zeidman, Peter Goel, Aimee Billig, Alexander J. Moran, Rosalyn Friston, Karl J. |
author_sort | Parr, Thomas |
collection | PubMed |
description | An interesting inference drawn by some COVID-19 epidemiological models is that there exists a proportion of the population who are not susceptible to infection—even at the start of the current pandemic. This paper introduces a model of the immune response to a virus. This is based upon the same sort of mean-field dynamics as used in epidemiology. However, in place of the location, clinical status, and other attributes of people in an epidemiological model, we consider the state of a virus, B and T-lymphocytes, and the antibodies they generate. Our aim is to formalise some key hypotheses as to the mechanism of resistance. We present a series of simple simulations illustrating changes to the dynamics of the immune response under these hypotheses. These include attenuated viral cell entry, pre-existing cross-reactive humoral (antibody-mediated) immunity, and enhanced T-cell dependent immunity. Finally, we illustrate the potential application of this sort of model by illustrating variational inversion (using simulated data) of this model to illustrate its use in testing hypotheses. In principle, this furnishes a fast and efficient immunological assay—based on sequential serology—that provides a (1) quantitative measure of latent immunological responses and (2) a Bayes optimal classification of the different kinds of immunological response (c.f., glucose tolerance tests used to test for insulin resistance). This may be especially useful in assessing SARS-CoV-2 vaccines. |
format | Online Article Text |
id | pubmed-8167139 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-81671392021-06-02 Dynamic causal modelling of immune heterogeneity Parr, Thomas Bhat, Anjali Zeidman, Peter Goel, Aimee Billig, Alexander J. Moran, Rosalyn Friston, Karl J. Sci Rep Article An interesting inference drawn by some COVID-19 epidemiological models is that there exists a proportion of the population who are not susceptible to infection—even at the start of the current pandemic. This paper introduces a model of the immune response to a virus. This is based upon the same sort of mean-field dynamics as used in epidemiology. However, in place of the location, clinical status, and other attributes of people in an epidemiological model, we consider the state of a virus, B and T-lymphocytes, and the antibodies they generate. Our aim is to formalise some key hypotheses as to the mechanism of resistance. We present a series of simple simulations illustrating changes to the dynamics of the immune response under these hypotheses. These include attenuated viral cell entry, pre-existing cross-reactive humoral (antibody-mediated) immunity, and enhanced T-cell dependent immunity. Finally, we illustrate the potential application of this sort of model by illustrating variational inversion (using simulated data) of this model to illustrate its use in testing hypotheses. In principle, this furnishes a fast and efficient immunological assay—based on sequential serology—that provides a (1) quantitative measure of latent immunological responses and (2) a Bayes optimal classification of the different kinds of immunological response (c.f., glucose tolerance tests used to test for insulin resistance). This may be especially useful in assessing SARS-CoV-2 vaccines. Nature Publishing Group UK 2021-05-31 /pmc/articles/PMC8167139/ /pubmed/34059775 http://dx.doi.org/10.1038/s41598-021-91011-x Text en © The Author(s) 2021, corrected publication 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Parr, Thomas Bhat, Anjali Zeidman, Peter Goel, Aimee Billig, Alexander J. Moran, Rosalyn Friston, Karl J. Dynamic causal modelling of immune heterogeneity |
title | Dynamic causal modelling of immune heterogeneity |
title_full | Dynamic causal modelling of immune heterogeneity |
title_fullStr | Dynamic causal modelling of immune heterogeneity |
title_full_unstemmed | Dynamic causal modelling of immune heterogeneity |
title_short | Dynamic causal modelling of immune heterogeneity |
title_sort | dynamic causal modelling of immune heterogeneity |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8167139/ https://www.ncbi.nlm.nih.gov/pubmed/34059775 http://dx.doi.org/10.1038/s41598-021-91011-x |
work_keys_str_mv | AT parrthomas dynamiccausalmodellingofimmuneheterogeneity AT bhatanjali dynamiccausalmodellingofimmuneheterogeneity AT zeidmanpeter dynamiccausalmodellingofimmuneheterogeneity AT goelaimee dynamiccausalmodellingofimmuneheterogeneity AT billigalexanderj dynamiccausalmodellingofimmuneheterogeneity AT moranrosalyn dynamiccausalmodellingofimmuneheterogeneity AT fristonkarlj dynamiccausalmodellingofimmuneheterogeneity |